VAR2 Pharmaceuticals is a privately held biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications. The most advanced drug candidate is a recombinant protein conjugated with a toxin.
Ando supports the company in defining their bioanalytical strategy, bioanalytical assay requirements and external partners, thereby, allowing further candidate characterization and toxicological investigations for preparation of the first clinical trial.
Ando spoke about the Importance of Immunogenicity Investigations in Clinical Development of Therapeutic Proteins at a workshop organized by Xendo GmbH, a ProPharma Group company, in collaboration with the biotech syndicate Berlin-Brandenburg bbb.
Y-mAbs Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center under an exclusive world-wide and research collaboration agreement.
PROvendis GmbH is a patent licensing agency for the universities of North Rhine-Westphalia, Germany.